skip to Main Content

Femur Fracture Outcomes Associated with Bisphosphonate Use

In clinical practice, bisphosphonate drugs are considered one of the main therapies for osteoporosis, based on strong clinical evidence of significant reduction in risk of hip, vertebral and non-vertebral fractures during the first 3-5 years of therapy. However, concerns have emerged regarding uncommon long term adverse outcomes in patients treated beyond this period. This study proposes to fill an important knowledge gap by examining the risk of atypical femur fracture in women who receive bisphosphonate treatment for less than 3 years compared to women who continue treatment beyond 3 years and to examine the association of long term continuation of bisphosphonate therapy and subsequent risk of atypical femur fracture.

Investigator: Lo, Joan

Funder: National Institute on Aging

Explore all studies and publications

Back To Top